MedTrace Logo

Vaccine Therapy in Treating Patients With Metastatic Cancer

NCT00020267 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2024-03-04

No results posted yet for this study

Summary

RATIONALE: Vaccines made from a peptide may make the body build an immune response and kill tumor cells.

PURPOSE: Randomized phase I trial to study the effectiveness of vaccine therapy in treating patients who have metastatic cancer that has not responded to previous therapy.

Conditions

Interventions

DRUG

interleukin-2

DRUG

MAGE-12 peptide vaccine

DRUG

Montanide ISA-51

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Francesco M. Marincola · National Cancer Institute (NCI)

Study Design

Purpose
TREATMENT

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00020267 on ClinicalTrials.gov